PharmaDrug Files For FDA Orphan Drug Designation For DMT In Kidney Transplantation and Expands on Its Psychedelics Strategy Post published:February 25, 2021 Post category:Press Release
Nova Mentis Autism Clinical Study Approved by Institutional Review Board Post published:February 25, 2021 Post category:Press Release
Center for Psychedelic Medicine Established at NYU Langone Health Post published:February 24, 2021 Post category:Press Release
Red Light Holland Announces Closing of $11.6 Million Bought Deal Financing Post published:February 24, 2021 Post category:Press Release
Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences Post published:February 24, 2021 Post category:Press Release
Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference Post published:February 24, 2021 Post category:Press Release
Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta Post published:February 24, 2021 Post category:Press Release
NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase 2 Human Clinical Trial Post published:February 24, 2021 Post category:Press Release
Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry in Jamaica; Hires Leading Psychiatrist as Medical Director Post published:February 23, 2021 Post category:Press Release
Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of Units Post published:February 23, 2021 Post category:Press Release